Hereditary angioedema (HAE) is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway.
Approximately one in every 10,000- 50,000 people are diagnosed with HAE; it is estimated that less than 8,000 people are diagnosed in the U.S and less than 15,000 people in Europe.
Most cases of HAE are caused by insufficient levels of functional C1-inhibitor, a protein that regulates plasma kallikrein, a critical mediator of bradykinin and edema.
On-demand treatments for HAE can help decrease the severity of an attack as it is occurring, and preventative treatments, taken chronically, can reduce the chance that an attack will occur. However, real need remains for effective treatment options with less burdensome administration, allowing patients to focus their time and energy on what matters most to them.
With STAR-0215, our goal is to provide an effective preventative treatment, dosed once every 3 months or longer, to decrease the burden of disease and burden of treatment for people with HAE.